Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Abstract Background Hepatitis B virus (HBV) reactivation is commonly seen in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Little is known about the risk of HBV reactivation after chimeric antigen receptor T-cell (CAR T) immunotherapy for the treatment of refractory/...

Full description

Bibliographic Details
Main Authors: Jia Wei, Xiaojian Zhu, Xia Mao, Liang Huang, Fankai Meng, Jianfeng Zhou
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Hepatitis B virus
Reactivation
Chimeric antigen receptor T-cell
Diffuse large B-cell lymphoma
Online Access:http://link.springer.com/article/10.1186/s40425-019-0790-y

Internet

http://link.springer.com/article/10.1186/s40425-019-0790-y

Similar Items